Literature DB >> 15737559

Early detection of breast and ovarian cancer in families with BRCA mutations.

H F A Vasen1, E Tesfay, H Boonstra, M J E Mourits, E Rutgers, R Verheyen, J Oosterwijk, L Beex.   

Abstract

Women at risk of breast and ovarian cancer due to a genetic predisposition may opt for preventive surgery or surveillance. The aim of this study was to determine the effectiveness of surveillance in families with a BRCA mutation. Sixty-eight BRCA-families underwent surveillance using annual mammography, transvaginal ultrasound, and estimation of CA125. Two hundred and two women had at least one breast examination, and 138 at least one examination of the ovaries. After a mean follow-up of 33 months, breast cancer was detected in 21 women, four with lymph node metastases. After a mean follow-up of 37 months, six advanced ovarian cancers were detected. The percentage of metastatic breast cancers in the current study appeared to be acceptable. However, because these women have a high-risk of developing breast cancer, they still have a substantial risk of developing metastatic disease under surveillance. Surveillance for ovarian cancer was not effective.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15737559     DOI: 10.1016/j.ejca.2004.10.029

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  22 in total

1.  Screening behavior in women at increased familial risk for breast cancer.

Authors:  Yoland C Antill; John Reynolds; Mary Anne Young; Judy A Kirk; Katherine M Tucker; Tarli L Bogtstra; Shirley S Wong; Tracy E Dudding; Juliana L Di Iulio; Kelly-Anne Phillips
Journal:  Fam Cancer       Date:  2006-07-07       Impact factor: 2.375

2.  Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Authors:  Ellen Warner; Kimberley Hill; Petrina Causer; Donald Plewes; Roberta Jong; Martin Yaffe; William D Foulkes; Parviz Ghadirian; Henry Lynch; Fergus Couch; John Wong; Frances Wright; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

3.  Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.

Authors:  Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

4.  Multimodality breast cancer screening in women with a familial or genetic predisposition.

Authors:  I Trop; L Lalonde; M H Mayrand; J David; N Larouche; D Provencher
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

5.  Genetic counseling content: How does it impact health behavior?

Authors:  Kimberly M Kelly; Lee Ellington; Nancy Schoenberg; Thomas Jackson; Stephanie Dickinson; Kyle Porter; Howard Leventhal; Michael Andrykowski
Journal:  J Behav Med       Date:  2014-12-23

6.  Hereditary Breast-Ovarian Cancer Team of the University Medical Centre Groningen (UMCG) - a Report.

Authors:  Marian Je Mourits; Jan C Oosterwijk; Jakob de Vries
Journal:  Hered Cancer Clin Pract       Date:  2005-11-15       Impact factor: 2.857

Review 7.  Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.

Authors:  Henry T Lynch; Murray Joseph Casey; Carrie L Snyder; Chhanda Bewtra; Jane F Lynch; Matthew Butts; Andrew K Godwin
Journal:  Mol Oncol       Date:  2009-02-21       Impact factor: 6.603

8.  Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.

Authors:  Adam N Rosenthal; Lindsay Fraser; Ranjit Manchanda; Philip Badman; Susan Philpott; Jessica Mozersky; Richard Hadwin; Fay H Cafferty; Elizabeth Benjamin; Naveena Singh; D Gareth Evans; Diana M Eccles; Steven J Skates; James Mackay; Usha Menon; Ian J Jacobs
Journal:  J Clin Oncol       Date:  2012-12-03       Impact factor: 44.544

9.  Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.

Authors:  Akiko Chiba; Tanya L Hoskin; Emily J Hallberg; Jodie A Cogswell; Courtney N Heins; Fergus J Couch; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2016-06-23       Impact factor: 5.344

10.  Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Authors:  Dimitra Sasaroli; George Coukos; Nathalie Scholler
Journal:  Biomark Med       Date:  2009-06-01       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.